Triazine compound salt, crystal form thereof, and production method therefor
The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.
1 . A crystal of pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate.
2 . The crystal according to claim 1 , wherein the salt is hydrobromide.
3 . The crystal according to claim 2 , having peaks at 8.8° 0.2°, 18.1°±0.2°, 20.9°±0.2°, and 25.6°±0.2° as diffraction angles expressed in 2θ in a powder X-ray diffraction spectrum.
4 . The crystal according to claim 2 , having an endothermic peak at 265 to 275° C. in a differential scanning calorimetry analysis.
5 . An aldosterone synthase inhibitor comprising the crystal according to claim 1 as an active ingredient.
6 . A pharmaceutical composition comprising the crystal according to claim 1 and a pharmaceutically acceptable additive.
7 . An aldosterone synthase inhibitor comprising the crystal according to claim 2 as an active ingredient.
8 . A pharmaceutical composition comprising the crystal according to claim 2 and a pharmaceutically acceptable additive.
9 . An aldosterone synthase inhibitor comprising the crystal according to claim 3 as an active ingredient.
10 . A pharmaceutical composition comprising the crystal according to claim 3 and a pharmaceutically acceptable additive.
11 . An aldosterone synthase inhibitor comprising the crystal according to claim 4 as an active ingredient.
12 . A pharmaceutical composition comprising the crystal according to claim 4 and a pharmaceutically acceptable additive.
13 . The crystal according to claim 3 further having peaks at 15.1°±0.2°, 17.5°±0.2°, 21.5°±0.2°, and 25.0°±0.2° as diffraction angles expressed in 2θ in a powder X-ray diffraction spectrum.
14 . An aldosterone synthase inhibitor comprising the crystal according to claim 13 as an active ingredient.
15 . A pharmaceutical composition comprising the crystal according to claim 14 and a pharmaceutically acceptable additive.